Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 9/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | ALPI | P09923 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | XIAP | P98170 | 1/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 3/20 | 0.60 |
| ▸ | NOS1 | P29475 | 3/20 | 0.60 |
| ▸ | NOS2 | P35228 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475725 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL288729 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL288636 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2314258 | 0.89 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL10888031 | 0.84 | SLC7A5 (0.46) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29217053 | 0.84 | GRIA2 (0.84) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL944210 | 0.84 | GRIA2 (0.84) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL6377902 | 0.83 | MAOA (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31370062 | 0.83 | MAOA (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31370551 | 0.82 | GRIA2 (0.58) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119410678-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | claimed |
| CN-112313336-B | Method for optimizing antibody expression | AMBRX公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4461318-A2 | NOVEL ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240350835-A1 | HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | AMBRX, INC. (US) | 2024-10-24 | — | — | US | claimed |
| US-12059473-B2 | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates | AMBRX, INC. (US) | 2024-08-13 | — | — | US | claimed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| CN-111417655-A | anti-CD3 antibody folate bioconjugates and uses thereof | 润俊(中国)有限公司 | 2020-07-14 | — | — | CN | claimed |
| WO-2020082057-A1 | INTERLEUKIN-10 POLYPEPTIDE CONJUGATES, DIMERS THEREOF, AND THEIR USES | AMBRX, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| WO-2019191728-A1 | HUMANIZED ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | AMBRX, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-10428333-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX INC. (US) | 2019-10-01 | — | — | US | claimed |
| EP-2337846-B1 | NON-NATURAL AMINO ACID REPLICATION-DEPENDENT MICROORGANISMS AND VACCINES | AMBRX INC (US) | 2018-01-17 | — | — | EP | claimed |
| US-9121025-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX, INC. (US) | 2015-09-01 | — | — | US | claimed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428333-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | BCAT2, IFNG, AADAT | SLC7A5 233/4885PTGS1 3543/4885ALPI 3402/4885 |
| US-12059473-B2 | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates | FOLH1, KLK3, PSMA6 | SLC7A5 1731/4885PTGS1 2401/4885ALPI 249/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | SLC7A5 136/4885PTGS1 4736/4885ALPI 2459/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | SLC7A5 1904/4885PTGS1 2032/4885ALPI 3829/4885 |
| US-20240350835-A1 | HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | FOLH1, KLK3, PSMA6 | SLC7A5 1803/4885PTGS1 2436/4885ALPI 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.